Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types

Experimental and Molecular Medicine

Volumn 48, Issue 7, 2016, Pages

  Hong, In Sun ^a  

^a Gachon University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; CANCER VACCINE;

CANCER CELL; CELL MATURATION; DENDRITIC CELL; HEMATOPOIESIS; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; LUNG CANCER; MACROPHAGE; METASTASIS; MONOCYTE; MULTIPLE CANCER; NONHUMAN; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; DISEASE EXACERBATION; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CLINICAL TRIALS, PHASE I AS TOPIC; DENDRITIC CELLS; DISEASE PROGRESSION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84976871152     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2016.64     Document Type: Review

References (105)

1. van de Laar L, Coffer PJ, Woltman AM. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood 2012; 119: 3383-3393.
2. Ohashi K, Kobayashi G, Fang S, Zhu X, Antonia SJ, Krieg AM et al. Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. J Pediatr Surg 2006; 41: 1361-1368.
3. Barreda DR, Hanington PC, Belosevic M. Regulation of myeloid development and function by colony stimulating factors. Dev Comp Immunol 2004; 28: 509-554.
4. Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer 2010; 10: 425-434.
5. Gutschalk CM, Yanamandra AK, Linde N, Meides A, Depner S, Mueller MM. GM-CSF enhances tumor invasion by elevated MMP-2,-9, and-26 expression. Cancer Med 2013; 2: 117-129.
6. Mascia F, Cataisson C, Lee TC, Threadgill D, Mariani V, Amerio P et al. EGFR regulates the expression of keratinocyte-derived granulocyte/macrophage colony-stimulating factor in vitro and in vivo. J Invest Dermatol 2010; 130: 682-693.
7. Rho CR, Park MY, Kang S. Effects of granulocyte-macrophage colonystimulating (GM-CSF) factor on corneal epithelial cells in corneal wound healing model. PLoS ONE 2015; 10: e0138020.
8. Lammel V, Stoeckle C, Padberg B, Zweifel R, Kienle DL, Reinhart WH et al. Hypereosinophilia driven by GM-CSF in large-cell carcinoma of the lung. Lung Cancer 2012; 76: 493-495.
9. Revoltella RP, Menicagli M, Campani D. Granulocyte-macrophage colonystimulating factor as an autocrine survival-growth factor in human gliomas. Cytokine 2012; 57: 347-359.
10. Perez FA, Fligner CL, Yu EY. Rapid clinical deterioration and leukemoid reaction after treatment of urothelial carcinoma of the bladder: possible effect of granulocyte colony-stimulating factor. J Clin Oncol 2009; 27: e215-e217.
11. Urdinguio RG, Fernandez AF, Moncada-Pazos A, Huidobro C, Rodriguez RM, Ferrero C et al. Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors. Cancer Res 2013; 73: 395-405.
12. Taghipour Fard Ardekani M, Malekzadeh M, Hosseini SV, Bordbar E, Doroudchi M, Ghaderi A. Evaluation of pre-treatment serum levels of IL-7 and GM-CSF in colorectal cancer patients. Int J Mol Cell Med 2014; 3: 27-34.
13. Montag M, Dyckhoff G, Lohr J, Helmke BM, Herrmann E, Plinkert PK et al. Angiogenic growth factors in tissue homogenates of HNSCC: expression pattern, prognostic relevance, and interrelationships. Cancer Sci 2009; 100: 1210-1218.
14. Gutschalk CM, Herold-Mende CC, Fusenig NE, Mueller MM. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res 2006; 66: 8026-8036.
15. Nebiker CA, Han J, Eppenberger-Castori S, Iezzi G, Hirt C, Amicarella F et al. GM-CSF production by tumor cells is associated with improved survival in colorectal cancer. Clin Cancer Res 2014; 20: 3094-3106.
16. Rigo A, Gottardi M, Zamo A, Mauri P, Bonifacio M, Krampera M et al. Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Mol Cancer 2010; 9: 273.
17. Shiomi A, Usui T. Pivotal roles of GM-CSF in autoimmunity and inflammation. Mediators Inflamm 2015; 2015: 568543.
18. Shi Y, Liu CH, Roberts AI, Das J, Xu G, Ren G et al. Granulocytemacrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res 2006; 16: 126-133.
19. Ponomarev ED, Shriver LP, Maresz K, Pedras-Vasconcelos J, Verthelyi D, Dittel BN. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J Immunol 2007; 178: 39-48.
20. Li R, Rezk A, Miyazaki Y, Hilgenberg E, Touil H, Shen P et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med 2015; 7: 310-166.
21. Tisato V, Secchiero P, Rimondi E, Gianesini S, Menegatti E, Casciano F et al. GM-CSF exhibits anti-inflammatory activity on endothelial cells derived from chronic venous disease patients. Mediators Inflamm 2013; 2013: 561689.
22. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen 2008; 16: 585-601.
23. Szabowski A, Maas-Szabowski N, Andrecht S, Kolbus A, Schorpp-Kistner M, Fusenig NE et al. c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell 2000; 103: 745-755.
24. Kingston D, Schmid MA, Onai N, Obata-Onai A, Baumjohann D, Manz MG. The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis. Blood 2009; 114: 835-843.
25. Murphy JM, Young IG. IL-3, IL-5, and GM-CSF signaling: crystal structure of the human beta-common receptor. Vitam Horm 2006; 74: 1-30.
26. McClure BJ, Hercus TR, Cambareri BA, Woodcock JM, Bagley CJ, Howlett GJ et al. Molecular assembly of the ternary granulocytemacrophage colony-stimulating factor receptor complex. Blood 2003; 101: 1308-1315.
27. Geijsen N, Koenderman L, Coffer PJ. Specificity in cytokine signal transduction: lessons learned from the IL-3/IL-5/GM-CSF receptor family. Cytokine Growth Factor Rev 2001; 12: 19-25.
28. Onetto-Pothier N, Aumont N, Haman A, Bigras C, Wong GG, Clark SC et al. Characterization of granulocyte-macrophage colony-stimulating factor receptor on the blast cells of acute myeloblastic leukemia. Blood 1990; 75: 59-66.
29. Hansen G, Hercus TR, McClure BJ, Stomski FC, Dottore M, Powell J et al. The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell 2008; 134: 496-507.
30. Suh HS, Kim MO, Lee SC. Inhibition of granulocyte-macrophage colonystimulating factor signaling and microglial proliferation by anti-CD45RO: role of Hck tyrosine kinase and phosphatidylinositol 3-kinase/Akt. J Immunol 2005; 174: 2712-2719.
31. Notarangelo LD, Pessach I. Out of breath: GM-CSFRalpha mutations disrupt surfactant homeostasis. J Exp Med 2008; 205: 2693-2697.
32. Lukens JR, Barr MJ, Chaplin DD, Chi H, Kanneganti TD. Inflammasomederived IL-1beta regulates the production of GM-CSF by CD4(+) T cells and gammadelta T cells. J Immunol 2012; 188: 3107-3115.
33. Sonderegger I, Iezzi G, Maier R, Schmitz N, Kurrer M, Kopf M. GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J Exp Med 2008; 205: 2281-2294.
34. Atanga E, Dolder S, Dauwalder T, Wetterwald A, Hofstetter W. TNFalpha inhibits the development of osteoclasts through osteoblastderived GM-CSF. Bone 2011; 49: 1090-1100.
35. Miyashita H, Katayama N, Fujieda A, Shibasaki T, Yamamura K, Sugimoto Y et al. IL-4 and IL-10 synergistically inhibit survival of human blood monocytes supported by GM-CSF. Int J Oncol 2005; 26: 731-735.
36. Dang PM, Elbim C, Marie JC, Chiandotto M, Gougerot-Pocidalo MA, El-Benna J. Anti-inflammatory effect of interleukin-10 on human neutrophil respiratory burst involves inhibition of GM-CSF-induced p47PHOX phosphorylation through a decrease in ERK1/2 activity. FASEB J 2006; 20: 1504-1506.
37. Kasper S, Kindler T, Sonnenschein S, Breitenbuecher F, Bohmer FD, Huber C et al. Cross-inhibition of interferon-induced signals by GM-CSF through a block in Stat1 activation. J Interferon Cytokine Res 2007; 27: 947-959.
38. Gabrusiewicz K, Ellert-Miklaszewska A, Lipko M, Sielska M, Frankowska M, Kaminska B. Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS ONE 2011; 6: e23902.
39. Nehme A, Edelman J. Dexamethasone inhibits high glucose-, TNF-alpha-, and IL-1beta-induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes. Invest Ophthalmol Vis Sci 2008; 49: 2030-2038.
40. Pastore S, Fanales-Belasio E, Albanesi C, Chinni LM, Giannetti A, Girolomoni G. Granulocyte macrophage colony-stimulating factor is overproduced by keratinocytes in atopic dermatitis. Implications for sustained dendritic cell activation in the skin. J Clin Invest 1997; 99: 3009-3017.
41. Reynolds G, Gibbon JR, Pratt AG, Wood MJ, Coady D, Raftery G et al. Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis. Ann Rheum Dis 2016; 75: 899-907.
42. Noster R, Riedel R, Mashreghi MF, Radbruch H, Harms L, Haftmann C et al. IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci Transl Med 2014; 6241-80.
43. Zinkernagel RM. On natural and artificial vaccinations. Annu Rev Immunol 2003; 21: 515-546.
44. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29: 235-271.
45. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715-727.
46. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009; 27: 83-117.
47. Chu Y, Wang LX, Yang G, Ross HJ, Urba WJ, Prell R et al. Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother 2006; 29: 367-380.
48. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000; 60: 3239-3246.
49. Qin Z, Noffz G, Mohaupt M, Blankenstein T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol 1997; 159: 770-776.
50. Gillessen S, Naumov YN, Nieuwenhuis EE, Exley MA, Lee FS, Mach N et al. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc Natl Acad Sci USA 2003; 100: 8874-8879.
51. Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000; 18: 1614-1621.
52. Rini BI, Weinberg V, Bok R, Small EJ. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colonystimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 2003; 21: 99-105.
53. Anderson PM, Markovic SN, Sloan JA, Clawson ML, Wylam M, Arndt CA et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 1999; 5: 2316-2323.
54. Yoshimura S, Bondeson J, Foxwell BM, Brennan FM, Feldmann M. Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. Int Immunol 2001; 13: 675-683.
55. Daro E, Pulendran B, Brasel K, Teepe M, Pettit D, Lynch DH et al. Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but notCD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J Immunol 2000; 165: 49-58.
56. Vremec D, Lieschke GJ, Dunn AR, Robb L, Metcalf D, Shortman K. The influence of granulocyte/macrophage colony-stimulating factor on dendritic cell levels in mouse lymphoid organs. Eur J Immunol 1997; 27: 40-44.
57. Zarei S, Schwenter F, Luy P, Aurrand-Lions M, Morel P, Kopf M et al. Role of GM-CSF signaling in cell-based tumor immunization. Blood 2009; 113: 6658-6668.
58. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
59. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5: 296-306.
60. Mach N, Dranoff G. Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 2000; 12: 571-575.
61. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
62. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998; 95: 13141-13146.
63. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocytemacrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003; 21: 624-630.
64. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviralmediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21: 3343-3350.
65. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999; 59: 5160-5168.
66. Baldwin GC, Gasson JC, Kaufman SE, Quan SG, Williams RE, Avalos BR et al. Nonhematopoietic tumor cells express functional GM-CSF receptors. Blood 1989; 73: 1033-1037.
67. Braun B, Lange M, Oeckler R, Mueller MM. Expression of G-CSF and GM-CSF in human meningiomas correlates with increased tumor proliferation and vascularization. J Neurooncol 2004; 68: 131-140.
68. Mueller MM, Fusenig NE. Constitutive expression of G-CSF and GM-CSF in human skin carcinoma cells with functional consequence for tumor progression. Int J Cancer 1999; 83: 780-789.
69. Mueller MM, Peter W, Mappes M, Huelsen A, Steinbauer H, Boukamp P et al. Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Am J Pathol 2001; 159: 1567-1579.
70. Obermueller E, Vosseler S, Fusenig NE, Mueller MM. Cooperative autocrine and paracrine functions of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the progression of skin carcinoma cells. Cancer Res 2004; 64: 7801-7812.
71. Mueller MM, Herold-Mende CC, Riede D, Lange M, Steiner HH, Fusenig NE. Autocrine growth regulation by granulocyte colonystimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am J Pathol 1999; 155: 1557-1567.
72. Ninck S, Reisser C, Dyckhoff G, Helmke B, Bauer H, Herold-Mende C. Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer 2003; 106: 34-44.
73. Pei XH, Nakanishi Y, Takayama K, Bai F, Hara N. Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Br J Cancer 1999; 79: 40-46.
74. Hu Z, Tan W, Zhang L, Liang Z, Xu C, Su H et al. A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF. J Cell Mol Med 2010; 14: 1836-1844.
75. Izard JP, Gore JL, Mostaghel EA, Wright JL, Yu EY. Persistent, unexplained leukocytosis is a paraneoplastic syndrome associated with a poor prognosis in patients with urothelial carcinoma. Clin Genitourin Cancer 2015; 13: e253-e258.
76. Wetzler M, Estrov Z, Talpaz M, Markowitz A, Gutterman JU, Kurzrock R. Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma. J Intern Med 1993; 234: 417-420.
77. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006; 24: 778-789.
78. Walid MS. Prognostic factors for long-term survival after glioblastoma. Perm J 2008; 12: 45-48.
79. Kohanbash G, McKaveney K, Sakaki M, Ueda R, Mintz AH, Amankulor N et al. GM-CSF promotes the immunosuppressive activity of gliomainfiltrating myeloid cells through interleukin-4 receptor-alpha. Cancer Res 2013; 73: 6413-6423.
80. Albulescu R, Codrici E, Popescu ID, Mihai S, Necula LG, Petrescu D et al. Cytokine patterns in brain tumour progression. Mediators Inflamm 2013; 2013: 979748.
81. Wang J, Yao L, Zhao S, Zhang X, Yin J, Zhang Y et al. Granulocyte-colony stimulating factor promotes proliferation, migration and invasion in glioma cells. Cancer Biol Ther 2012; 13: 389-400.
82. Karcher S, Steiner HH, Ahmadi R, Zoubaa S, Vasvari G, Bauer H et al. Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer 2006; 118: 2182-2189.
83. Jung KH, Chu K, Lee ST, Kim SJ, Sinn DI, Kim SU et al. Granulocyte colony-stimulating factor stimulates neurogenesis via vascular endothelial growth factor with STAT activation. Brain Res 2006; 1073-1074: 190-201.
84. Ohki Y, Heissig B, Sato Y, Akiyama H, Zhu Z, Hicklin DJ et al. Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils. FASEB J 2005; 19: 2005-2007.
85. Curran CS, Evans MD, Bertics PJ. GM-CSF production by glioblastoma cells has a functional role in eosinophil survival, activation, and growth factor production for enhanced tumor cell proliferation. J Immunol 2011; 187: 1254-1263.
86. Kucerova L, Matuskova M, Hlubinova K, Altanerova V, Altaner C. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer 2010; 9: 129.
87. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010; 138: 2101-14 e5.
88. Danese S, Malesci A, Vetrano S. Colitis-associated cancer: the dark side of inflammatory bowel disease. Gut 2011; 60: 1609-1610.
89. Verreck FA, de Boer T, Langenberg DM, Hoeve MA, Kramer M, Vaisberg E et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA 2004; 101: 4560-4565.
90. Demirci U, Coskun U, Sancak B, Ozturk B, Bahar B, Benekli M et al. Serum granulocyte macrophage-colony stimulating factor: a tumor marker in colorectal carcinoma? Asian Pac J Cancer Prev 2009; 10: 1021-1024.
91. Tomita T, Fujii M, Tokumaru Y, Imanishi Y, Kanke M, Yamashita T et al. Granulocyte-macrophage colony-stimulating factor upregulates matrix metalloproteinase-2 (MMP-2) and membrane type-1 MMP (MT1-MMP) in human head and neck cancer cells. Cancer Lett 2000; 156: 83-91.
92. Shafiq M, Venkateshiah S. Hematologic abnormalities associated with lung carcinoma. Respir Care 2011; 56: 523-526.
93. Shalom G, Sion-Vardy N, Dudnik J, Ariad S. Leukemoid reaction in lung cancer patients. Isr Med Assoc J 2010; 12: 255-256.
94. Hauber HP. Paraneoplastic syndromes in lung cancer. Pneumologie 2011; 65: 347-358.
95. Bahar B, Acedil Ayc Iota B, Coskun U, Buyukberber S, Benekli M, Yildiz R. Granulocyte colony stimulating factor (G-CSF) and macrophage colony stimulating factor (M-CSF) as potential tumor markers in non small cell lung cancer diagnosis. Asian Pac J Cancer Prev 2010; 11: 709-712.
96. Mroczko B, Szmitkowski M. Hematopoietic cytokines as tumor markers. Clin Chem Lab Med 2004; 42: 1347-1354.
97. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE 2008; 3: e3077.
98. Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, Qu X et al. Granulocytecolony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci USA 2010; 107: 21248-21255.
99. Aliper AM, Frieden-Korovkina VP, Buzdin A, Roumiantsev SA, Zhavoronkov A. A role for G-CSF and GM-CSF in nonmyeloid cancers. Cancer Med 2014; 3: 737-746.
100. Ruff MR, Farrar WL, Pert CB. Interferon gamma and granulocyte/macrophage colony-stimulating factor inhibit growth and induce antigens characteristic of myeloid differentiation in small-cell lung cancer cell lines. Proc Natl Acad Sci USA 1986; 83: 6613-6617.
101. Yamashita Y, Nara N, Aoki N. Antiproliferative and differentiative effect of granulocyte-macrophage colony-stimulating factor on a variant human small cell lung cancer cell line. Cancer Res 1989; 49: 5334-5338.
102. Berdel WE, Danhauser-Riedl S, Steinhauser G, Winton EF. Various human hematopoietic growth factors (interleukin-3, GM-CSF, G-CSF) stimulate clonal growth of nonhematopoietic tumor cells. Blood 1989; 73: 80-83.
103. Dedhar S, Gaboury L, Galloway P, Eaves C. Human granulocytemacrophage colony-stimulating factor is a growth factor active on a variety of cell types of nonhemopoietic origin. Proc Natl Acad Sci USA 1988; 85: 9253-9257.
104. Onetto N. Extra hematopoietic effect of colony-stimulating factors. Blood 1989; 74: 1446-1447.
105. Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 2010; 16: 2715-2728.